Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on EXL01 for Preventing Crohn's Disease Recurrence After Surgery in Patients

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Crohn's disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The trial will test a new treatment called EXL01, which is a type of live biotherapeutic product, meaning it contains living microorganisms that are intended to help maintain or restore a healthy balance of bacteria in the gut. The study will also use a matching placebo for comparison.

The purpose of this study is to evaluate the safety and effectiveness of EXL01 in preventing the recurrence of Crohn's disease after surgery. Participants in the study will be randomly assigned to receive either the EXL01 treatment or a placebo. The study will last for about six months, during which participants will take the treatment orally in capsule form. Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the progress of their condition.

The main goal is to compare the outcomes of those treated with EXL01 to those who receive the placebo, specifically looking at the recurrence of Crohn's disease symptoms after surgery. This will be assessed using a method called endoscopy, which involves using a camera to look inside the digestive tract. The study aims to provide valuable information on whether EXL01 can help prevent the return of Crohn's disease symptoms after surgery, potentially offering a new option for managing this challenging condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization

    Upon joining the study, participants are randomly assigned to receive either the EXL01 capsule or a matching placebo. This process is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.

  2. Step 2

    Medication administration

    Participants take the assigned capsule orally. The specific dosage and frequency are determined by the study protocol and are followed throughout the trial duration.

  3. Step 3

    Monitoring and assessments

    Regular assessments are conducted to monitor the participant's health and response to the treatment. These include endoscopic evaluations at various intervals, with a primary focus at 6 months post-surgery.

    The modified Rutgeerts score is used to assess the condition of the intestines. This score is determined through endoscopic procedures, which involve using a camera to view the inside of the intestines.

  4. Step 4

    Data collection

    Throughout the trial, data is collected on various health indicators, including the Crohn’s Disease Activity Index (CDAI), patient-reported outcomes, and levels of specific proteins and bacteria in the body.

    These assessments help determine the effectiveness of the treatment in preventing the recurrence of Crohn's disease after surgery.

  5. Step 5

    End of treatment

    The study concludes with a final assessment at 24 weeks or at the end of treatment. This includes a comprehensive evaluation of the participant's condition using endoscopy and other diagnostic tools.

    The results are analyzed to determine the success of the treatment in preventing the recurrence of Crohn's disease.

Who can join the trial?

4 criteria

  • The patient must be a male or female who is **18 years or older** at the time they agree to participate in the study.
  • The patient must have been diagnosed with **Crohn's disease (CD)**, which affects the **ileum** (a part of the small intestine) for at least **3 months** before the screening process.
  • The patient must have had a **surgery** called **ileocecal resection** or **ileo-colonic resection** (removal of a part of the intestine) between **5 days to 5 weeks** before being randomly assigned to a treatment group.
  • The patient should not be scheduled to receive any treatment for Crohn's disease or **anti-TNF agents** (medications that reduce inflammation) in the **6 months** following the surgery.

Who cannot join the trial?

10 criteria

  • Patients who have not had surgery related to **Crohn's disease**. **Crohn's disease** is a condition that causes inflammation in the digestive tract.
  • Patients who are not within the specified age range for the study.
  • Patients who are not able to follow the study procedures or attend follow-up visits.
  • Patients who have other medical conditions that might interfere with the study results.
  • Patients who are pregnant or breastfeeding.
  • Patients who are participating in another clinical trial at the same time.
  • Patients who have a history of allergic reactions to the study medication or similar medications.
  • Patients who have used certain medications that might affect the study results.
  • Patients who have a history of substance abuse or alcohol dependency.
  • Patients who have a mental health condition that might affect their ability to participate in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

EXL01 is a medication being studied to see if it can help prevent Crohn's Disease from coming back after surgery. Crohn's Disease is a condition that causes inflammation in the digestive tract, and sometimes surgery is needed to remove the affected parts. This medication is being tested to see if it can keep the disease from returning after such surgeries.

What is already known about the treatment

EXL01 – This medication is administered orally and is currently being studied in clinical trials for its potential to prevent the recurrence of Crohn's disease after surgery. It is in the experimental phase, with ongoing research to evaluate its safety and effectiveness. The main therapeutic indication is to reduce the risk of Crohn's disease returning after surgical intervention. EXL01 works by targeting specific pathways in the immune system to reduce inflammation and prevent disease recurrence. It is classified as an investigational drug, and its exact mechanism of action at the molecular level is still under study.

Investigated diseases

Crohn's disease – Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract, primarily affecting the small intestine and colon. It is characterized by periods of flare-ups and remission, where symptoms can vary in intensity. During flare-ups, individuals may experience abdominal pain, diarrhea, fatigue, and weight loss. The inflammation can penetrate deep into the layers of the bowel tissue, leading to complications such as strictures or fistulas. Over time, the disease can cause damage to the digestive tract, potentially affecting its ability to absorb nutrients. The progression of Crohn's disease is unpredictable, with symptoms and severity differing from person to person.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-511357-22-00Protocol codeREMIND-2024-001Estimated enrolment80 patientsSponsorGroupe De Recherche Sur Les Maladies Inflammatoires Digestives

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).